These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33471673)

  • 21. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
    Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
    Liang CY; Chen DY; Mao CT; Hsieh IC; Hung MJ; Wang CH; Wen MS; Cherng WJ; Chen TH
    Medicine (Baltimore); 2018 Dec; 97(52):e13844. PubMed ID: 30593182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.
    Hao Y; Yang Y; Wang Y; Li J
    Curr Med Res Opin; 2022 Oct; 38(10):1663-1672. PubMed ID: 35575139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
    Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D
    Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome.
    Ma X; Dong L; Shao Q; Cheng Y; Lv S; Sun Y; Shen H; Wang Z; Zhou Y; Liu X
    Cardiovasc Diabetol; 2020 Mar; 19(1):31. PubMed ID: 32156279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Anyanwagu U; Mamza J; Donnelly R; Idris I
    Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
    Lin JC; Shau WY; Lai MS
    Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
    Chan SY; Ou SM; Chen YT; Shih CJ
    Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].
    Yang BG; Yu XP; Chen F; Lyu SZ; Li Q; He JQ; Yuan F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jan; 45(1):19-25. PubMed ID: 28100341
    [No Abstract]   [Full Text] [Related]  

  • 32. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Safety and Efficacy of Staged Percutaneous Coronary Intervention for Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease.
    Cui K; Lyu S; Song X; Liu H; Yuan F; Xu F; Zhang M; Wang W; Zhang M; Zhang D; Tian J
    Am J Cardiol; 2019 Aug; 124(3):334-342. PubMed ID: 31174834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
    Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
    Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin degludec is associated with less frequent and milder hypoglycemia in insulin-deficient patients with type 1 diabetes compared with insulin glargine or detemir.
    Iwasaki S; Kozawa J; Kimura T; Fukui K; Iwahashi H; Imagawa A; Shimomura I
    Diabetol Int; 2017 Jun; 8(2):228-236. PubMed ID: 30603326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK.
    Husemoen LLN; Mørch LS; Christensen PK; Hartvig NV; Feher MD
    Diabetes Ther; 2021 May; 12(5):1299-1311. PubMed ID: 33721211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.